Can immune cells predict ovarian cancer outcomes?

NCT ID NCT03862677

Recruiting now Knowledge-focused Sponsor: Leiden University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is looking at immune markers in the blood of 300 women with ovarian cancer to see if they can predict how the disease will progress. It is an observational study, meaning no treatment is given. The goal is to better understand the role of the immune system in ovarian cancer prognosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors better predict how ovarian cancer will progress, leading to more personalized treatment plans.
What could go wrong: This is an observational study, not a treatment trial. It aims to gather information, not to test a new therapy. The findings may not directly change patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial fallopian tube cancer fallopian tube neoplasm ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPITHELIAL OVARIAN CANCER

Contacts and locations

Locations

Leiden University Medical Center
RECRUITING

Leiden, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.